Abstract
Septic shock has a crude mortality rate of 45% and claims the lives of 90 000 people each year in the USA alone.1 An epidemiological study from France of over 100 000 intensive care unit (ICU) admissions indicates the incidence of septic shock before or following admission to ICU is rising and now affects almost 10% of this patient population.2 Given the scale and associated costs of this problem,34 it is not surprising that developing solutions has been a focus of researchers, clinicians, and the pharmaceutical industry. Despite many past disappointments particularly with antagonists of endogenous mediators,5 some recent approaches have shown promise in prevention or treatment of sepsis and septic shock. They include tight glycaemic control, early haemodynamic goal-directed therapy, infusion of activated protein C, and use of corticosteroids.6

This publication has 35 references indexed in Scilit: